Published on
February 2, 2026
- 13:45 GMT
AdvanCell and 48Hour Discovery Enter Exclusive Agreement to Advance a Lead-212 Radioligand Therapy Program
AdvanCell and 48Hour Discovery Announce Collaboration and Exclusive Licensing Agreement to Develop a Lead-212 Alpha Radioligand Therapy Program EDMONTON, ALBERTA, CANADA, February 2, 2026 /EINPresswire.com/ -- AdvanCell, a clinical-stage …
Distribution channels:
Business & Economy, Chemical Industry
...
